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The interaction between sphingosine-1-phosphate 
(S1P) and the cognate receptor S1P1 is believed to 
mediate the egress of lymphocytes from secondary lym-
phoid tissues (SLT) by overcoming the retention signals 
operated by the chemokine receptor CCR7,1 which is 
expressed by naive T cells, central memory T lympho-
cytes (TCM), and B cells, but not by terminally differen-
tiated effector memory T cells (TEM).2,3 Therefore, 
fingolimod, a high-affinity agonist for four of the five 
known receptors,4,5 by downmodulating S1P1, retains 
naive, TCM, and B lymphocytes in SLT, while TEM are 
spared from this effect.1,6 TCM lack direct inflammatory 
function and represent a clonally expanded, antigen-
primed population that migrates to SLT and recirculates 
on a regular basis between SLT and blood; upon stimu-
lation, TCM can generate new waves of effector cells. In 
contrast, TEM represent a readily available pool of anti-
gen-primed cells that can enter and reside in non-lym-
phoid tissues, such as the central nervous system (CNS), 
to mediate inflammatory reactions or cytotoxicity.2,3 As 
more than 90% of T lymphocytes that accumulate in the 
cerebrospinal fluid (CSF) of patients with multiple scle-
rosis (MS) are TCM, their specific retention in SLT may 
be one of the mechanisms underlying the therapeutic 
effect of fingolimod in MS.7
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Background: Fingolimod inhibits lymphocyte egress from lymphoid tissues, thus altering the composi-
tion of the peripheral lymphocyte pool of multiple sclerosis patients.
Objective: The objective of this paper is to evaluate whether fingolimod determines a decrease of newly 
produced T- and B-lymphocytes in the blood and a reduction in the T-cell receptor repertoire diversity 
that may affect immune surveillance.
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limod-treated patients. The decrease was particularly evident in the T-cell compartment. T-cell repertoire 
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Because peripheral lymphocytes represent only 
approximately 2% of lymphocyte total body stores,8 
and because the functions of sequestered lymphocytes 
appear to be preserved, it has been proposed that the 
key features of the immune system are likely to be 
maintained during fingolimod therapy.6,9 However, 
because S1P and S1P1 also appear to control T-cell 
egress from thymus in the mouse model,10 fingolimod 
may modify the thymic output of recent thymic emi-
grants (RTE), which are the youngest subset of periph-
eral T cells. This is a key question, because these cells 
mainly contribute to the recovery from lymphopenia11 
and play a central role in generating and maintaining 
the diversity of T-cell receptor (TCR) repertoires,12 
which is mandatory for efficient immune responses to 
infections and vaccines. Whether fingolimod influ-
ences B-cell emigration from the bone marrow is also 
presently unclear. Indeed, while earlier data reported 
that B lymphocyte egress from the production site was 
only weakly influenced by S1P signalling,10 later 
results indicated that immature B-lymphocyte output 
from bone marrow was reduced.13
Therefore, in view that the number of newly gener-
ated lymphocytes is decreased14 and the TCR reper-
toire is restricted in MS patients,15 compared to those 
of healthy controls (HCs), in this study we analyzed 
whether fingolimod treatment has a further impact on 
these alterations, which may impair the immune 
response against infections and vaccines.
Methods
Protocol approvals and patient consent
The study was approved by the institutional ethical 
review board (number 24401). Written informed con-
sent was obtained from all individuals participating in 
the study.
Patients
For this cohort study, 18 patients (11 females; age 
36.9 ± 11.6 years) with relapsing–remitting MS, who 
started fingolimod treatment in the clinical practice 
(0.5 mg once daily), were consecutively enrolled 
from April to October 2012 at the MS center of the 
city hospital. Six of them switched to fingolimod 
from interferon beta and 11 from natalizumab, after a 
minimum of a three-month washout period; one 
patient was naive from therapy and was treated with 
fingolimod following the Italian Medicines Agency 
(AIFA) indications. Samples were obtained just 
before fingolimod therapy initiation, and then six and 
12 months thereafter. Changes of clinical parameters 
during therapy are reported in Table 1. Two out of 18 
patients discontinued fingolimod and returned to 
natalizumab after four and 10 months of treatment 
and were therefore excluded from the statistical anal-
yses. In eight out of the 11 patients receiving fingoli-
mod after natalizumab, samples had been previously 
obtained before natalizumab initiation, and after six, 
12, and 24 to 52 additional months of therapy. Results 
from samples obtained before therapy were compared 
with those of age- and sex-matched HCs.
Quantification of lymphocyte subpopulations
Newly produced T and B cells were measured by 
quantifying the number of T-cell receptor excision 
circles (TRECs) and K-deleting recombination exci-
sion circles (KRECs) in peripheral blood mononu-
clear cells (PBMCs) using a duplex quantitative 
real-time polymerase chain reaction (PCR) performed 
on the 7500 Fast Real-Time PCR (Applied 
Biosystems), as previously reported.16 Results were 
expressed either as copies/106 PBMC or copies/ml.16 
RTE and naive CD8+T cells, as well as immature and 
naive B cells, were identified using a FACSCanto II 
cytometer and results were analyzed with FACSDiva 
Table 1. Clinical features of the patients treated with fingolimod.
Clinical features T6 T12
EDSS (median (range)) 3.5 (1 to 6.5) 4.5 (1 to 6.5)
EDSS change from baselinea (median (range)) 0 (−2.5 to −0.5) 0 (−2.5 to 1.5)
ARR (mean (SD)) – 0.56 (0.81)
Relapse-free patients (% (95% CI)) 52.9 (31.0 to 73.8) 56.2 (33.2 to 76.9)
Increase in MRI lesion load (median (range)) 0 (0 to 1) 0 (0 to 3)
Patients with increased MRI lesion load (% (95% CI)) 12.5 (3.5 to 36.0) 23.1 (8.2 to 50.3)
Seriousb infections 0 0
a EDSS at baseline (median (range)): 3.75 (1 to 6.5). bHerpes virus-family-related infection or lower respiratory tract. EDSS: Ex-
panded Disability Status Scale; ARR: annualized relapse rate; T6 and T12: six and 12 months of therapy; MRI: magnetic resonance 
imaging; CI: confidence interval.
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software (BD Biosciences), as previously described.17 
Data were reported as percentage and as absolute 
count per µl of blood.
TCR repertoire analysis
The analysis of TCR beta variable (TCRBV) families 
by spectratyping was performed as previously 
described,18 starting from 500 ng of total RNA 
extracted from at least 2 × 106 cells. The first strand of 
the TCRB chain-specific cDNA was utilized for multi-
plex PCRs, allowing the detection of 23 functional 
TCRBV gene families.19 The length distribution of 
fluorescent-labelled PCR products was analyzed on an 
ABI 3130 analyzer (Applied Biosystems). Distribution 
of fragment lengths, number of detectable peaks per 
TCRBV element, and area under the curve were calcu-
lated by Peak Scanner software version 1.0 (Applied 
Biosystems). Data were analyzed and reported in three 
different ways. First, the complexity of individual 
TCRBV complementarity determining region 3 
(CDR3) size distributions was determined by counting 
the number of distinct peaks within each TCRBV fam-
ily, which varied from one to 13 in HCs and from 0 to 
10 in MS patients; the sum of the peak number of all 
23 TCRBV families determined the overall TCR com-
plexity score within each individual. Then, the CDR3 
size distributions of each TCRBV family were classi-
fied into one of the following five categories: normal 
(≥7 peaks, Gaussian distribution), shifted (≥7 peaks, 
deviation from Gaussian distribution), restricted (<7 
peaks prominent deviation from Gaussian distribu-
tion), mono/oligoclonal (one or two dominant peaks),20 
undetectable (absence of detectable peaks); for each 
participant, the proportions of TCRBV families with a 
CDR3 distribution belonging to each one of these cat-
egories were calculated. Finally, TCRBV distribution 
perturbations were calculated with the generalized 
Hamming distance method,21 by “subtracting” from 
the CDR3 length distribution of each TCRBV of a 
patient the average Gaussian-like CDR3 length distri-
bution obtained by analyzing a “reference group” 
composed of eight HCs. When a TCRBV family was 
not represented (no detectable peaks), the condition of 
maximal perturbation was reached, and its value was 
arbitrarily set to 100%.
Statistical analysis
Analyses of variance for repeated measures based on 
linear mixed models, followed by Bonferroni cor-
rected post-hoc tests, were performed to compare the 
immune parameters between HCs and patients before 
and during treatment. The models were fitted with 
time and treatment as covariates (without interaction, 
because HCs were not followed over time), and with a 
random intercept between subjects. A similar proce-
dure with time as the only covariate was employed to 
perform the longitudinal analysis of immune parame-
ters in patients switching from natalizumab to fingoli-
mod. For all analyses, TREC and KREC values, as 
well as the absolute cell counts, were log-transformed, 
whereas the proportion of CDR3 distributions belong-
ing to the five distribution categories underwent an 
angular transformation (i.e. arcsine of their root-
square). The total complexity scores and average per-
turbation percentages were analyzed by nonparametric 
methods (Mann-Whitney and Wilcoxon test, with 
Bonferroni corrected p values). Perturbations were 
also analyzed at the individual TCRBV-family level, 
and were considered significantly abnormal when 
their values were beyond the mean + 3 SD of the per-
turbations calculated in HCs.21
Results
Levels of newly produced T and B lymphocytes
The mean level of TRECs/ml in blood samples of MS 
patients obtained before fingolimod therapy initia-
tion, which appeared only slightly but not signifi-
cantly reduced compared to HCs, significantly and 
progressively decreased after six and 12 months of 
therapy (Figure 1(a), left). In most patients, TREC/ml 
levels were below the lowest values observed in HCs 
and were undetectable in two patients at six months 
and in five patients at 12 months of therapy. Similar 
results were obtained when TREC quantities were not 
corrected for the number of lymphocytes (which were 
significantly reduced at six months of therapy (mean: 
697/µl (confidence interval (CI) 482–912); p < 0.001) 
and T12 (mean: 688/µl (CI 474–903); p < 0.001) in 
comparison to baseline (mean: 2385/µl (CI 2170–
2600); p < 0.001) and monocytes (which were con-
stant during the therapy), and therefore were expressed 
per 106 PBMCs (Figure 1(a), right). Analogously, a 
fingolimod-related reduction was observed if TREC 
level was related to the number of circulating CD3+ 
lymphocytes (Supplementary Figure 1). The number 
of KRECs, if calculated per ml of blood and per 106 
PBMC, significantly decreased during the follow-up, 
but the reduction was less severe than that of TRECs 
and remained comparable at six and 12 months of 
therapy (Figure 1(b)). On the contrary, KRECs 
increased if their level was related to CD19+ cell num-
ber (Supplementary Figure 1).
The fingolimod-induced decrease of absolute number 
of TRECs and KRECs was confirmed by flow cytom-
etry. In fact, the number and percentage of RTE, 
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identified as CD4+ cells expressing the CCR7, CD45RA 
and CD31 markers (Figure 1(c)), and of CD8+CCR7+ 
CD45RA+ naive lymphocytes (Figure 1(d)) were sig-
nificantly reduced after six and 12 months of therapy. 
However, when the percentage of RTE was calculated 
not over the total CD4+ population, but within the naive 
CD4+ subset, there were no differences in samples 
obtained before and during fingolimod therapy 
(Supplementary Figure 2). The number of immature 
CD19+CD21− and naive CD19+CD21+IgD+CD27− B 
cells, which are the subsets containing the highest 
number of KRECs,22 decreased significantly in treated 
patients from baseline to six and 12 months of therapy 
(Figure 1(e) and (f), left); on the contrary, the percent-
age of immature B cells progressively increased 
(Figure 1(e), right), while that of B naive cells remained 
unmodified (Figure 1(f), right).
No differences were found comparing patients who 
shifted to fingolimod from natalizumab with those 
who came from interferon beta (IFNβ) therapies, with 
the only exception of a lower number of naive B cells 
Figure 1. Quantification of newly produced T and B lymphocytes.
TRECs (a) and KRECs (b) in fingolimod-treated patients were evaluated by real-time PCR before therapy initiation (F0) and after six 
(F6) and 12 (F12) months and then compared to that of HCs. Values were expressed as number of TRECs and KRECs per ml of blood 
and per 106 PBMCs. Absolute number and percentage (over the total CD4+ lymphocytes) of RTE (c), naive CD8+ cells (d), immature (e) 
and naive B cells (f) were obtained by cytofluorimetric analysis in ex-vivo samples at the indicated time points. TRECs: T-cell receptor 
excision circles; KRECs: K-deleting recombination excision circles; HCs: healthy controls; RTE: recent thymic emigrants; PBMC: 
peripheral blood mononuclear cells; PCR: polymerase chain reaction; F0, F6, F12: 0, 6, 12 months of fingolimod treatment. ** p < 0.01; 
***p < 0.001.
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before fingolimod initiation in patients who had pre-
viously received natalizumab (data not shown).
Because of the availability of samples obtained before 
and during natalizumab therapy (at six, 12 and 24-to-
52 months), at the washout, and then at six and 12 
months of fingolimod therapy in eight patients, we had 
the possibility to analyze the changes of newly pro-
duced T and B lymphocytes in condition of both high 
(after six months of natalizumab: 3635/µl (3115–4155) 
and after 12 months: 3496/µl (CI 2976–4016) vs. 
before natalizumab: 2046/µl (CI 1526–2566); p < 
0.001) and low number of peripheral lymphocyte 
counts (see values before). The levels of TRECs, 
KRECs, as well as of T and B subpopulations, 
increased after six months of natalizumab therapy 
(Figure 2) and remained stable thereafter; but then, 
after six months of fingolimod administration, TRECs, 
RTE and naive CD8+ cells significantly decreased if 
compared to the washout time point, as well as from 
six to 12 months (Figure 2). KRECs, immature and 
naive B cells decreased only in the first six months 
Figure 2. Newly produced T and B lymphocytes before and after the switch from natalizumab to fingolimod.
The values of TRECs, KRECs, RTE, naive CD8+ cells, immature and naive B cells in eight individual patients (#1 to #8) who received 
natalizumab and then switched to fingolimod are displayed. Samples were obtained before each therapy initiation and after six and 12 
months, and at variable intervals between 24 and 52 months of therapy with natalizumab.
TRECs: T-cell receptor excision circles; KRECs: K-deleting recombination excision circles; RTE: recent thymic emigrants; N0, N6, 
N12: 0, six, 12 months of natalizumab treatment; WO/F0: sample obtained after the washout from natalizumab, but before fingolimod 
treatment; F6, F12: six, 12 months of fingolimod treatment.
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after fingolimod initiation, and then remained stably 
low. Of note, in patients #7 and #8, higher values 
reflect the reversal to natalizumab treatment earlier 
than six and 12 months, respectively.
TCR repertoire diversity
The overall complexity score, which is an indicator of 
TCR repertoire heterogeneity, was lower in patients 
with MS before fingolimod therapy initiation com-
pared to HCs. This parameter further decreased in 
patients who received fingolimod for 12 months, indi-
cating that the drug might augment some TCR reper-
toire restrictions already present in the pre-treatment 
samples (Figure 3(a)). Accordingly, the mean propor-
tion of TCRBV elements with restricted and mono/
oligoclonal profiles or with undetectable TCRBV 
families was significantly higher (59% (CI 53–66)) in 
samples of fingolimod-treated patients than in pre-
treatment samples (36% (CI 30–42)) and in samples 
of HCs (6% (CI 2–11); Figure 3(b)). The analysis of 
the average percentage of TCRBV perturbations cal-
culated in patients, treated or not treated with fingoli-
mod, confirmed the finding of a higher proportion of 
TCRBV elements with a distorted CDR3 size distri-
bution during the therapy (Figure 3(c)).
Altogether, these data demonstrated that TCR reper-
toire was significantly altered in fingolimod-treated 
patients. On the contrary, the total complexity score 
and the average TCRBV perturbations were unmodi-
fied in the natalizumab-treated patients (Supplementary 
Figure 3).
Figure 3. Analysis of TCRBV repertoire diversity.
(a) Total complexity scores across the 23 TCRBV families analyzed in HCs and in MS patients before (F0) and after 12 months of 
fingolimod therapy (F12). Each dot represents one individual. (b) Percentage of normally distributed, shifted/skewed, restricted, mono/
oligoclonally expanded and undetectable (absence of detectable peaks) TCRBV elements. Displayed bar lengths were calculated as 
the group means of the within-patient proportions of TCRBV elements belonging to each one of the five proposed categories. The 
reported significance was obtained comparing the within-patient proportions of pooled (mono/oligoclonal + restricted + undetectable) 
vs. (shifted + normal) categories between HCs, F0 and F12 by analysis of variance. (c) Percentages of TCRBV perturbations in HCs, 
F0 and F12. Each dot represents the global average perturbation of the TRCBV repertoire in one patient. (d) Heatmap representing the 
CDR3 distribution perturbation at the single-TCRBV, single-patient level, in seven of the eight patients who switched from natalizumab 
to fingolimod. Boxed squares represent the TCRBV families whose perturbations are higher than the mean+3SD of the value seen in the 
corresponding TCRBV family in HCs. The proportion of these over-perturbed TCRBV elements is indicated in column “*”. Patients #7 
and #8 switched back to natalizumab treatment before reaching time point F12.
TCRBV: T-cell receptor variable beta; HCs: healthy controls; MS: multiple sclerosis patients; CDR3: complementarity determining 
region 3; N0: before natalizumab; N12: 12 months after natalizumab initiation; WO/F0: after natalizumab washout, but before assuming 
fingolimod; F6, F12 = six, 12 months of fingolimod treatment. ** p < 0.01; *** p < 0.001.
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In the eight patients who shifted from natalizumab to 
fingolimod and from whom longitudinal samples 
were available during these therapies, TCRBV pertur-
bations were also evaluated at the single-patient level. 
We found that the number of perturbed TCRBV fami-
lies increased from pre-natalizumab to 12 months of 
fingolimod treatment, but, surprisingly, in all but one 
of them also increased during the washout (Figure 
3(d)), when fingolimod had not been initiated and the 
levels of newly produced lymphocytes had not 
decreased yet. In the two patients who discontinued 
fingolimod and returned to natalizumab, this increase 
in TCR repertoire perturbation was clearly dampened 
by the second therapy switch. Some over-perturbed 
TCRBV families, which were present before therapy 
initiation, disappeared after 12 months of natali-
zumab, but returned after 12 months of fingolimod 
(TCRBV12, 21 and 23 of patients #1, for instance; 
Figure 3(d)), while other TCRBV alterations persisted 
during the all observation period (TCRBV6, 17 and 
23 in patients #4; and TCRBV12, and 16 in patients 
#5; Figure 3(d)). Other perturbed TCRBV families 
appeared only after natalizumab therapy (TCRBV16 
in patients #1; TCRBV3 in patients #3; TCRBV9 and 
14 in patient #2; and TCRBV9, 20 and 24 in patient 
#4; Figure 3(d)), or become evident at the washout 
time point and remained during fingolimod treatment. 
No correlation was found between the extent of fin-
golimod-induced lymphopenia and the degree of rep-
ertoire perturbation (data not shown). For a 
representative example of the CDR3 spectratype 
changes reflecting alterations in the TCRBV reper-
toire during time, see also Supplementary Figure 4.
Discussion
In physiological conditions, the size of the peripheral 
T-cell pool is maintained relatively constant through-
out life. In fact, despite their continuous turnover and 
thymic export,23,24 the number of T cells is kept large 
enough to adequately protect against pathogens, but 
small enough to avoid taxing the host resources. 
Using a mice model, Houston et al.25 demonstrated 
that when the peripheral lymphoid compartment is 
full, newly produced T lymphocytes are not accepted 
into the periphery and persist less well than mature 
naive T cells. On the contrary, under lymphopenic 
conditions, when these T cells would be particularly 
important for replenishing the TCR diversity, RTE are 
able to fill the void effectively. This mechanism, 
apparently, is altered in MS patients during fingoli-
mod treatment because we found that in the condition 
of severe fingolimod-induced lymphopenia the levels 
of TRECs, RTE, and naive CD8 were dramatically 
reduced. While this is in line with data obtained in 
mice, in which fingolimod appears to inhibit mature 
thymocyte emigration from the thymus to the periph-
ery,26 the similar percentage of RTE, calculated within 
the naive CD4 subset, observed before and during 
therapy, suggests that thymic output is not per se 
heavily affected by the therapy. This could be a key 
point to understand why the incidence of infections is 
only slightly increased during the treatment with 
fingolimod.27,28
If the increased number of TREC+ cells has been pro-
posed as one of the reasons for the enlargement of the 
TCR repertoire observed in natalizumab-treated 
patients,20,29 their reduction in the peripheral blood 
may be responsible for the profound TCR repertoire 
restrictions that we have observed in fingolimod-
treated patients. The low levels of circulating newly 
produced T cells and the reduced peripheral T-cell 
diversity could raise the concern that fingolimod may 
impair both the development of immune responses to 
novel antigens and the steady-state immune response 
to chronic or latent viral infections. It is well known 
that the ability of T-cells to respond to foreign anti-
gens relies on the recognition of antigenic epitopes by 
diverse TCR, and the presence of heterogeneous T 
cells is crucial in mounting immune responses against 
pathogens. In fact, skewing of the repertoire leads to 
missing immune responses, as seen in human immu-
nodeficiency virus (HIV) infection,30 aging,11,12 and 
various immune deficiencies.31,32 This may help 
explain the small increase in the number and, in rare 
cases, severity of some infections, in particular herpes 
virus related,27,28,33 even considering that the variation 
in total lymphocyte counts was barely correlated to 
infection rates in the patients of fingolimod phase III 
trials.34 This is an intriguing point because natali-
zumab-treated patients who, on the contrary, have 
been shown to have an increased thymic output17 and 
a broader TCR repertoire,20 are at high risk of severe 
John Cunningham (JC) virus infections. However, it 
has been reported that an MS patient treated with 
natalizumab who had a very low number of TRECs 
and RTE in the presence of a restricted repertoire 
developed a progressive multifocal leukoencephalop-
athy.18 Therefore, these two drugs appear to have an 
impact on the immune surveillance that is not only 
related to the integrity of the T-cell compartment.
A limitation of the present study is that we cannot for-
mally establish whether the reduced TCR repertoire 
was related to the altered composition of the periph-
eral blood T-cell subsets or occurs independently of 
this. However, in allo-stem cell-transplanted patients 
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peripheral repertoire was skewed when T cells 
expressed a memory phenotype, but the diversity pro-
gressively increased with the appearance of naive T 
cells.35
Another point emerging from our data is that the inter-
ruption of natalizumab therapy and three to six months 
of washout may also lead to an increased restriction of 
the TCR repertoire, even if, at the same time, the num-
ber of TRECs, RTE or naive T cells are unmodified. 
Furthermore, the detailed analysis of TCR repertoire 
also demonstrated that the drug-induced appearance/
disappearance of clonal/oligoclonal expansions was a 
very dynamic phenomenon accruing quickly after the 
therapy switch.
Although less completely than for thymic or SLT 
egress,1 the S1P system appears also to contribute to 
B-cell egress from the bone marrow. We found that the 
number of KRECs, if calculated per ml of blood or per 
106 PBMCs, as well as the number of immature and 
naive B cells, were decreased in peripheral blood of 
fingolimod-treated patients. However, differently 
from Nakamura et al.,36 who demonstrated that the fre-
quency of B-cell populations within CD19+ B lympho-
cytes was not significantly altered by fingolimod 
therapy, we found that the number of KRECs related 
to circulating CD19+ lymphocytes and the percentage 
of immature B cells were increased.
Although the number of analyzed patients is too small 
to draw any conclusions with regards to potential 
infectious complications that may occur in treated 
patients and the results do not have direct clinical 
implications, our findings may be useful for further 
understanding the mode of action of immunotherapies 
for MS. Indeed, because of the longitudinal design of 
the study, the availability of some samples from 
patients who were followed for five years, the updated 
techniques used, and the paired sampling analysis of 
the data, the study has enough strength to shed light 
on the fine immunological changes induced by two 
drugs that, by interfering with the migration of leuko-
cytes, have revolutionized MS treatment.
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